

# Dose-Response Relationships Between Plasma Adrenocorticotropin (ACTH), Cortisol, Aldosterone, and 18-Hydroxycorticosterone After Injection of ACTH-(1-39) or Human Corticotropin-Releasing Hormone in Man\*

W. OELKERS, T. BOELKE, AND V. BÄHR, WITH THE TECHNICAL ASSISTANCE OF P. EXNER, B. FAUST, AND H. HARENDT

Division of Endocrinology, Department of Internal Medicine, Klinikum Steglitz, Freie Universität Berlin, Berlin, West Germany

**ABSTRACT.** The effects of sc injections (at 1500 h) of increasing amounts of synthetic human ACTH-(1-39) (1.25-30 µg) on plasma ACTH, cortisol, aldosterone, and 18-hydroxycorticosterone were compared with those of iv injections of 30 and 100 µg synthetic human CRH in nine normal men. Five micrograms of ACTH, sc, was the lowest dose that significantly increased plasma levels of the three steroids. CRH (30 µg, iv) increased plasma cortisol and 18-hydroxycorticosterone, but not aldosterone, while 100 µg CRH also raised aldosterone secretion. The dose-response curve (peak plasma ACTH level vs. maximum increment of plasma cortisol within the first hour) was initially

very steep. Plasma ACTH levels between 50 and 60 ng/L (11-13 pmol/L) stimulated cortisol to almost 80% of the maximal increment obtained with plasma ACTH levels above 300 ng/L (>66 pmol/L). This dose-response relationship is similar to that found in clinical tests of the pituitary-adrenal axis (insulin test, metyrapone test). The effects of plasma ACTH released by CRH on cortisol secretion were not significantly different from those of injected ACTH. Our results argue against the hypothesis that the effect of CRH on steroid secretion is mediated or modulated by POMC-derived peptides other than ACTH. (*J Clin Endocrinol Metab* 66: 181, 1988)

NEY *et al.* (1) were the first to investigate the relationship between plasma ACTH and plasma 17-hydroxycorticosteroid concentration during the infusion of ACTH-(1-39) (porcine) for 24 h. In their study, maximum 17-OHCS levels were reached with plasma ACTH concentrations between 2 and 5 mU/mL (~200-500 ng/L or 44-110 pmol/L). Fehm *et al.* (2) concluded recently that plasma ACTH levels much higher than those in the early morning hours in man are necessary for maximal acute stimulation of cortisol secretion, as occurs during insulin-induced hypoglycemia. The relationship between peak plasma ACTH and cortisol levels after the iv injection of incremental doses of ovine (3) or human (4) CRH suggests that cortisol secretion is nearly maximally stimulated at ACTH levels around 40 or 50 ng/L (8.8-11 pmol/L). Since plasma ACTH cannot be increased above 80 ng/L (17.6 pmol/L) by injecting even 30 µg/kg ovine

(o) CRH (3), we investigated ACTH-cortisol dose response relationships by injecting incremental sc doses of human (h) ACTH-(1-39). The results are compared with those obtained after iv injection of two standard doses of hCRH. Since the effectiveness of CRH as a stimulator of aldosterone is also debated (5-7), we measured, in addition, plasma aldosterone and one of its potential precursors, 18-hydroxycorticosterone(18-OHCS), after ACTH and CRH injections.

## Subjects and Methods

Nine normal men were studied. Their age varied between 20 and 32 yr, and their body weight between 65 and 78 kg. They were nonsmokers and were eating an unrestricted diet. The protocol of the study was approved by the Ethical Committee of the Klinikum Steglitz, and each man gave written consent to participate in the study.

ACTH or hCRH injections were always given at 1500 h the afternoon after the men had eaten a light fat-free meal at 1200 h and had been quietly seated in an armchair for 1 h. At 1400 h a plastic cannula for blood sampling was placed in a large forearm vein. Blood was collected in tubes containing EDTA for measurements of plasma ACTH, cortisol, aldosterone,

Received May 18, 1987.

Address requests for reprints to: W. Oelkers, M.D., Department of Internal Medicine, Klinikum Steglitz, Freie Universität Berlin, Hindenburgdamm 30, 1000 Berlin 45, West Germany.

\* This work was supported by a grant of the Deutsche Forschungsgemeinschaft (Oe 47/8-2).

18-OH-B at 1445, 1455, 1515 (after CRH only), 1530, 1545, 1600, 1630, and 1700 h. The tubes were put into crushed ice and centrifuged immediately at 3°C, and the plasma was stored for up to 6 weeks at -70°C before RIA.

Synthetic hACTH-(1-39) was purchased from Peninsula Laboratories, Inc. (Belmont, CA; lot 009309). Before the study was begun, 500 µg ACTH were dissolved in 50 mL sterile 150 nmol/L saline and passed through Millipore filters (0.22 µm; Millex-GS, Millipore Corp., Bedford, MA) into 20 sterile plastic vials which were immediately frozen at -70°C. Each aliquot was thawed 1 h before injection. Dilutions of the thawed ACTH solutions (theoretic concentration, 10 µg/mL) were compared repeatedly with the standard ACTH used as constituent of the ACTH RIA kit (see below). In six assays, the ACTH injection solution was found to contain  $10.8 \pm 1.1$  (±SD) µg/mL ACTH. The ACTH solution was drawn into sterile plastic syringes of appropriate size and injected sc, using very fine needles, into upper arm contralateral to that which had been cannulated. More than 1 mL ACTH solution had to be given, two or three were injected. The injections caused almost no pain. Each man received 1.25, 2.5, 5, 10, 20, and 30 µg ACTH in a random order at intervals of at least 3 days. On other occasions, men received 30 and 100 µg hCRH (CRF Bissendorf-tide GmbH, Wedemark, West Germany), iv, instead of ACTH. No adverse effects of ACTH injection were noted. The men reported a mild warm flush after CRH injection, which persisted for less than 5 min.

ACTH was measured in unextracted plasma using commercial RIA kits obtained from Compagnie Oris Industrie S.A. (Gif Yvette, France). These kits contained a rabbit anti-ACTH body directed against the 1-24 sequence of ACTH. hACTH-(9), calibrated against the ACTH MRC standard 74/555, was used as standard. The antigen-antibody complex was created by adding a reagent containing an insoluble complex of sheep antirabbit γ-globulin. The minimum ACTH concentration detectable varied between 5 and 7 ng/mL (1.1-1.5 pmol/L). The intraassay variability at a mean ACTH concentration of 1.1 ng/L (4.4 pmol/L) was 11% (n = 9). The interassay variability of a plasma pool with a mean ACTH concentration of 1.1 ng/L (11.2 pmol/L; n = 18) was 8.6%. In 40 normal men (40 yr of age), plasma ACTH levels (0800-0900 h) ranged from less than 5 (n = 4) to 46.3 ng/L (<1.1-10.2 pmol/L), with a mean of  $19.7 \pm 10.3$  (±SD) ng/L ( $4.3 \pm 2.3$  pmol/L). The mean ACTH levels at 1500 h in the study subjects were  $9.5 \pm 6.9$  ng/L ( $2.1 \pm 0.35$  pmol/L).

Plasma cortisol was measured using CEA Sorin kits with poly-coated tubes. The sensitivity of the assay was between 10 and 20 nmol/L. The intraassay variabilities at different cortisol levels (100, 350, and 1000 nmol/L; n = 15 each) were 3.9%, and 4.5%, respectively. The interassay variabilities at the same concentration levels were 9.6%, 5.7%, and 5.5%, respectively. The areas under the curve for ACTH and cortisol were calculated by multiplying the mean of the hormone concentrations at the adjacent times of measurement up to 60 min by the time (in minutes), followed by summing the results of the individual time segments. Basal secretion (preinjection hormone level × 60) was then subtracted.

Plasma aldosterone and 18-OH-B were measured by RIA in

the blood samples drawn before and at 1530, 1545, and 1600 h after ACTH injection. After hCRH injection, these steroids were measured at 1515, 1530, and 1545 h. The RIAs were preceded by paper chromatographic purification of the steroids (8, 9).


All ACTH and cortisol samples were analyzed in duplicate, and all samples from an individual man were analyzed at the same time. Statistical analyses of the results were performed using a STATS 2 program of Statsoft, Inc. (Tulsa, OK) and an IBM computer. Since all studies were performed in the same subjects, the Wilcoxon test for correlated samples was used exclusively.


## Results

Figure 1 shows the mean plasma ACTH and cortisol concentrations after the injection of 2.5-30 µg ACTH, sc, and 100 µg CRH, iv. After the administration of 1.25 µg ACTH (not shown), neither plasma ACTH nor cortisol increased significantly. Plasma ACTH did rise after the injection of 2.5 µg ACTH, sc, from  $11.3 \pm 2.3$  (±SEM) to  $18.4 \pm 1.2$  ng/L ( $P < 0.05$ ), but plasma cortisol did not increase significantly. After 5 µg ACTH, plasma ACTH rose to  $27.8 \pm 1.4$  ng/L (6.2 pmol/L), and cortisol rose significantly to 399 nmol/L (Fig. 1 and Table 1). In the first half hour after the administration of 100 µg ACTH, cortisol rose almost as high as after the larger ACTH doses, although the mean peak ACTH level after 10 µg ACTH, sc, was much lower than that after 20 or 30 µg ACTH. After the higher ACTH doses, the rise in plasma cortisol lasted longer than after the smaller ACTH doses. The plasma ACTH peak after iv injection of 30 or 100 µg hCRH was earlier than the plasma ACTH peak after sc ACTH injection. The peak plasma ACTH and cortisol levels after 100 µg CRH, iv, were similar to those after 10 µg ACTH, sc, while the responses to 30 µg CRH, iv, resembled those to 5 µg ACTH, sc (Figs. 1 and 3). The areas under the plasma ACTH and cortisol curves in the first 60 min after injection also were similar for 5 µg ACTH and 30 µg hCRH and for 10 µg ACTH and 100 µg hCRH, as shown in Table 1.

Figure 2 is a plot of the peak plasma ACTH levels after the different dosages of ACTH sc or CRH iv as a function of the highest plasma cortisol increment within the first 60 min after injection. The dose-response curve initially was steep, but above peak ACTH levels of about 60 ng/L (13 pmol/L) it became very flat. However, the cortisol response to 20 µg ACTH was significantly higher ( $P < 0.05$ ) than that to 10 µg ACTH, but the cortisol responses to 20 and 30 µg ACTH were not significantly different. The dose-response relationships after injection of ACTH sc or CRH iv fell almost on the same line (Fig. 2), although the timing of the peaks was different (Figs. 1 and 3).

Figure 3 shows the effects of the incremental ACTH





(12). They were able to mimic spontaneously occurring single plasma ACTH and cortisol peaks by injecting small doses of hCRH iv.

The fact that an acute increase in plasma ACTH to about 60 ng/L (13.2 pmol/L) stimulates cortisol secretion almost maximally is important for clinical tests of the pituitary-adrenal axis. In most normal subjects, plasma ACTH rises to levels above 150 or 200 ng/L (33 or 44 pmol/L) after insulin-induced hypoglycemia or metyrapone testing (13, 14). In patients with moderately impaired ACTH secretion, these tests will not reveal the disturbance if only the adrenal (plasma cortisol or 11-deoxycortisol) response is measured, since an increase in plasma ACTH to 50 or 60 ng/L (11 or 13 pmol/L) will lead to almost normal stimulation of the adrenal cortex.

After comparison of steroid responses to insulin and metyrapone tests in a large number of patients with pituitary disease (15), we performed the short metyrapone test according to the method of Jubiz *et al.* (16), with plasma ACTH and 11-deoxycortisol measurements. 0800 h in 7 normal subjects and 35 patients with pituitary disease. In the normal subjects, plasma ACTH increased to 170–360 ng/L (37–79 pmol/L) and 11-deoxycortisol to 210–500 nmol/L. In the patients with pituitary disease, in whom plasma ACTH increased to between 50 and 210 ng/L (11 and 46 pmol/L), 11-deoxycortisol increased into the normal range after metyrapone injection. Only in patients with ACTH increases to less than 55 ng/L (12 pmol/L) was the rise of 11-deoxycortisol subnormal. This finding indicates that the results presented in this paper are applicable to the interpretation of clinical tests.

Reports on the effect of CRH on plasma aldosterone are controversial. Müller *et al.* (5) found no significant rise in plasma aldosterone after injection of 100 µg CRH into normal subjects. We also found no significant rise in plasma aldosterone in nine normal recumbent subjects given 100 µg oCRH at 1700 h (17), while cortisol and 18-OH-B increased markedly. Hermus *et al.* (6) and Naglen *et al.* (7), however, found plasma aldosterone to rise slightly but significantly after the injection of 200 µg CRH, iv, in normal subjects.

In this study, both plasma aldosterone and 18-OH-B were significantly stimulated by the same threshold dose of ACTH-(1–39) (5 µg) that significantly stimulated cortisol. However, with all ACTH and hCRH doses studied, the variability of the aldosterone and 18-OH-B responses was greater than that of the cortisol responses. While 30 µg CRH significantly stimulated plasma cortisol and 18-OH-B ( $P < 0.01$ ), plasma aldosterone rose minimally. hCRH (100 µg) significantly stimulated aldosterone 45 min after injection, but the response was smaller than that of cortisol and 18-OH-B. Since 30 µg hCRH elicited plasma ACTH responses similar to those occurring after

the injection of 5 µg ACTH, it appears that the injected ACTH was more effective in stimulating aldosterone secretion than was the ACTH released by hCRH. This suggests the existence of POMC peptides or other CRH-induced factors that inhibit the aldosterone response to ACTH released by CRH. Altogether, the smaller aldosterone responses to ACTH and CRH, compared with those of cortisol and 18-OH-B, may be due to the relatively high sodium intake of our subjects, which can blunt aldosterone responses nonspecifically (18, 19). Differences in dietary sodium also may explain the contradictory findings of different researchers with regard to aldosterone stimulation by CRH (5–7).

CRH injection stimulates not only the release of ACTH but also that of other POMC-derived peptide (20, 21).  $\beta$ -Endorphin,  $\beta$ -lipotropin, and pro- $\gamma$ -melanotropin have been reported to stimulate aldosterone secretion or enhance the effects of ACTH on aldosterone secretion (22–24). We found that hCRH-released ACTH tended to stimulate aldosterone secretion less than injected ACTH. This finding argues against the physiological significance of potential aldosterone-stimulating factors, other than ACTH, that may be released after hCRH injection.

### References

1. Ney RL, Shimizu N, Nicholson WE, Island DP, Liddle GW 1963 Correlation of plasma ACTH concentration with adrenocortical response in normal human subjects, surgical patients, and patients with Cushing's disease. *J Clin Invest* 42:1669
2. Fehm HL, Klein E, Holl R, Voigt KH 1984 Evidence of extrapituitary mechanisms mediating the morning peak of plasma cortisol in man. *J Clin Endocrinol Metab* 58:410
3. Orth DN, Jackson RV, de Cherney GS, de Bold CR, Alexander AN, Island DP, Rivier J 1983 Effect of synthetic ovine corticotropin releasing factor. Dose response of plasma adrenocorticotropin and cortisol. *J Clin Invest* 71:587
4. Schürmeyer TH, Avgerinos PC, Gold PW, Gallucci WT, Tomai TP, Cutler GB, Loriaux DL, Chrousos GP 1984 Human corticotropin-releasing factor in man: pharmacokinetic properties and dose-response of plasma adrenocorticotropin and cortisol secretion. *J Clin Endocrinol Metab* 59:1103
5. Müller OA, Dörr HG, Hagen B, Stalla GK, von Werder K 1982 Corticotropin releasing factor stimulation test in normal controls and patients with disturbances of the hypothalamo-pituitary-adrenal axis. *Klin Wochenschr* 60:1485
6. Hermus ARMM, Pieters GFFM, Smals AGH, Benraad ThJ, Kloppenborg PWC 1984 Plasma adrenocorticotropin, cortisol, and aldosterone responses to corticotropin-releasing factor: modulatory effect of basal cortisol levels. *J Clin Endocrinol Metab* 58:187
7. Conaglen JV, Donald RA, Espiner EA, Livesey JH, Nicholls MG 1984 The effect of ovine corticotropin-releasing factor on catecholamine, vasopressin, and aldosterone secretion in normal man. *J Clin Endocrinol Metab* 58:463
8. Schöneschöfer M 1977 Simultaneous determination of eight adrenal steroids in human serum by radioimmunoassay. *J Steroid Biochem* 8:995
9. Belkien L, Schöneschöfer M, Oelkers W 1980 Development and characterization of antisera to 18-hydroxy-corticosterone and 18-hydroxydeoxycorticosterone. *Steroids* 35:427
10. Oelkers W, Köhler A, Belkien L, Fuchs-Hammoser R, Maiga M, Scherer B, Weber PC 1982 Studies on the mechanism by which ACTH stimulates renin activity and angiotensin II formation in

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.